Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence

被引:0
作者
Tongtong Kan
Shupeng Zhang
Shengtao Zhou
Ya Zhang
Yun Zhao
Yinghua Gao
Tao Zhang
Feng Gao
Xin Wang
Linjie Zhao
Mengsu Yang
机构
[1] City University of Hong Kong,Department of Biomedical Sciences
[2] Beijing Institute of Basic Medical Sciences,Department of Pathology
[3] The Second Affiliated Hospital of Shandong First Medical University,Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and State Key Labor
[4] West China Hospital,Department of Pathology
[5] Sichuan University,Department of Biostatistics, School of Public Health
[6] Taian Tumor Prevention and Treatment Hospital,Key Laboratory of Biochip Technology, Shenzhen Research Institute
[7] Shandong University,undefined
[8] City University of Hong Kong,undefined
来源
Oncogene | 2022年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61+ “stress” subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5+ cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61+ relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.
引用
收藏
页码:895 / 906
页数:11
相关论文
共 212 条
  • [1] Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
  • [2] Miller KD(2013)Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Nat Rev Cancer 13 273-82
  • [3] Jemal A(2010)Ovarian cancer development and metastasis Am J Pathol 177 1053-64
  • [4] Kipps E(2017)Optimizing treatment in recurrent epithelial ovarian cancer Expert Rev Anticancer Ther 17 1147-58.
  • [5] Tan DS(2009)Ovarian cancer Lancet 374 1371-82
  • [6] Kaye SB(2004)Cancer of the ovary N Engl J Med 351 2519-29
  • [7] Lengyel E(1996)Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1-6
  • [8] Corrado G(2005)Cellular processing of platinum anticancer drugs Nat Rev Drug Disco 4 307-20
  • [9] Salutari V(2003)Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action Curr Cancer Drug Targets 3 193-203
  • [10] Palluzzi E(2016)Metastatic colonization by circulating tumour cells Nature 529 298-306